Prokineticin 受体 (PKR) 是一类 G 蛋白偶联受体,包含 PKR1 和 PKR2 两种亚型,通过与内源性配体 prokineticin (PK1和PK2)结合,参与调控多种重要的生理和病理过程。研究表明,PKR 在血管生成、神经发生、疼痛感知、生殖功能以及昼夜节律调节等方面发挥关键作用[1]。
PKR1 主要在心血管系统和外周组织中表达,参与血管新生和心脏保护;而 PKR2 则主要分布于中枢神经系统,调控神经元发育和突触可塑性。PKR 激活后主要通过 Gq/11 蛋白偶联通路,刺激磷脂酶C (PLC) 活化,进而促进细胞内钙离子释放和蛋白激酶C (PKC)激活[2]。
Prokineticin Receptors (PKRs) are a class of G protein-coupled receptors comprising two subtypes, PKR1 and PKR2. They bind to endogenous ligands prokineticin (PK1 and PK2) and play pivotal roles in regulating various important physiological and pathological processes. Research has demonstrated that PKRs are critically involved in angiogenesis, neurogenesis, pain perception, reproductive functions, and circadian rhythm regulation[1].
PKR1 is primarily expressed in the cardiovascular system and peripheral tissues, where it participates in angiogenesis and cardioprotection, while PKR2 is predominantly distributed in the central nervous system, modulating neuronal development and synaptic plasticity . Upon activation, PKRs mainly signal through the Gq/11 protein-coupled pathway, stimulating phospholipase C (PLC) activation, which subsequently induces intracellular calcium release and protein kinase C (PKC) activation[2].
7DG (7-Desacetoxy-6,7-dehydrogedunin) 是一种 PKR 抑制剂、P2X7 嘌呤能受体抑制剂以及美白剂,其结合于 PKR 的 ATP 催化结构域外,阻断 PKR 不依赖激酶活性的蛋白质-蛋白质相互作用,抑制 PKR 的磷酸化与活性,破坏 ASC 组装及 caspase-1 激活,并抑制 NLRP1 炎症小体的激活,同时抑制细胞焦亡 (pyroptosis) 及 ATP-P2X7 信号通路,消除 ATP 诱导的 MITF、酪氨酸酶 (tyrosinase)、PMEL/gp100 表达水平及黑色素含量的升高,在体外培养的皮肤中发挥美白作用,可用于慢性阻塞性肺疾病、痛风、2 型糖尿病、阿尔茨海默病以及色素沉着过度性皮肤病的相关研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号